ArticleImmunity, inflammation and disease2026
The Factors Influencing the Efficacy of Pregabalin Combined With Lidocaine in the Treatment of Postherpetic Neuralgia Patients: An Analysis.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Factors Influencing the Efficacy of Pregabalin Combined With Lidocaine in the Treatment of Postherpetic Neuralgia Patients: An Analysis.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aims to analyze the primary factors influencing the therapeutic effect of pregabalin combined with lidocaine in patients with post-herpetic neuralgia (PHN).
methodsClinical data of 97 PHN patients admitted to our hospital from January 2022 to October 2024 were retrospectively analyzed. All patients received pregabalin combined with lidocaine treatment. Treatment efficacy was assessed using the numerical rating scale (NRS) for pain, dividing patients into effective (≥ 50% NRS reduction) and ineffective groups. Univariate and multivariate logistic regression analyses identified the main influencing factors. Pearson correlation analysis explored relationships between factors and therapeutic effect. Receiver operating characteristic (ROC) curves evaluated predictive values.
resultsPosttreatment, 77 patients (79.38%) were classified as responders, while 20 (20.62%) were nonresponders. Age (OR: 0.163, 95% CI: 0.036-0.535), illness duration (OR: 0.098, 95% CI: 0.015-0.369), pain severity (OR: 2.794, 95% CI: 1.362-6.566), and presence of concomitant immunosuppressive diseases (OR: 0.194, 95% CI: 0.030-0.742) were key determinants. Positive correlations were found between illness duration (r = 0.352), pain severity (r = -0.279), immunosuppressive diseases (r = 0.231), and treatment effectiveness (p < 0.05). Age showed a negative correlation (r = 0.301, p < 0.05). ROC curves indicated AUCs for age, illness duration, pain severity, and immunosuppressive diseases were 0.685, 0.716, 0.691, and 0.368, respectively. Combined, these factors had a higher predictive value (AUC = 0.734).
conclusionAge ≥ 65 years, illness duration ≥ 3 months, severe pain, and the presence of concomitant diseases causing immunosuppression are the main factors influencing the effectiveness of combined pregabalin and lidocaine treatment for PHN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.